Sino-American immunotherapy-focused biotech LTZ Therapeutics and UK pharma major GSK have entered into a strategic research ...

Just a few weeks after the company announced licensing agreements with Empirico and Syndivia, GSK announced a strategic ...

GSK & LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology: London, UK Thursday, November 20, 2025, 09:00 Hrs [IST] GSK plc and LTZ Therapeutics ...

Moderna has announced a $140 million investment to enhance its Massachusetts manufacturing capacity, a move that supports ...

GSK teams with LTZ Therapeutics to co-develop next-gen myeloid-cell engager immunotherapies in oncology leveraging LTZ’s ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

I’ve noticed the smiles and a lot of 180 turns when people realize what they’re seeing. The whole reason I did it was to make ...

GSK (GSK) and LTZ Therapeutics announced a strategic research collaboration to advance the development of novel myeloid cell engagers, MCEs, to ...

Agios Pharmaceuticals Inc. reported top-line data from its 52-week Rise Up trial testing oral pyruvate kinase activator mitapivat in sickle cell disease (SCD), which hit statistical significance on ...

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title, registration ...

Publicize your non-profit’s community events, fundraisers and club meetings for free in The Stroller. Send information at ...

Immunotherapy-focused biotech company LTZ Therapetics Inc. and GSK plc are partnering to develop up to four potential first-in-class myeloid cell engagers using LTZ’s immune-engager platform to target ...